Trending News
News
News
Thermo Fisher Scientific Opens new Facility and Demonstration Laboratory in Switzerland
The new facility houses Thermo Fisher’s analytical instrument operations and consolidates the Flux Instruments and Spectronex product lines.
News
The NIMH Psychoactive Drug Screening Program and Collaborative Drug Discovery Provide a Chemically Searchable GPCR
CDD's web-based software now hosts the largest open-access chemical sub-structure and similarity searchable GPCR Ki database.
News
Scientists Decode Genome of Parasite that Causes Relapsing Malaria
The findings shed light on distinctive genetic features of Plasmodium vivax, and may lead to new tools to prevent and treat P. vivax malaria.
News
Sagent Pharmaceuticals and Itochu Chemical Frontier Corporation Announce Development and Manufacturing Collaboration
ICF will supply injectable products for which Sagent will obtain U.S. regulatory approval and market in the United States.
News
Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study Under IND
Debiopharm Group announced that the first healthy elderly subjects have been randomised in a clinical bioequivalence bridging study, conducted in the United States under IND (Investigational New Drug).
News
Simcyp Launches Virtual ‘Lab Rat’ for Drug Development
New simulator to help refine animal testing and streamline pharmaceutical research.
News
MDS Analytical Technologies Acquires Blueshift Biotechnologies
MDS Analytical Technologies announced it has acquired California-based Blueshift Biotechnologies (Sunnyvale, CA) for $13 million.
News
Pharmaceutical Profiles Completes First-of-a-Kind Integrated Clinical Study to Address all Aspects of Drug Bioavailability
Pharmaceutical Profiles Ltd has completed a groundbreaking clinical study designed to address a range of factors critical to early drug development decision making in a single, integrated protocol.
News
FDA Advisory Panel to Discuss Genzyme’s Myozyme BLA on Tuesday
Genzyme Corporation today announced that its U.S. Biologic License Application (BLA) for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale will be discussed this Tuesday, October 21st, at a public meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee in Silver Spring, Maryland.
News
Provectus Pharmaceuticals Adds Fourth Center to Phase 2 Clinical Trial of PV-10
Provectus Pharmaceuticals, Inc. has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a fourth major center.
Advertisement